Literature DB >> 17275681

Association of body iron stores with low molecular weight iron and oxidant damage of human atherosclerotic plaques.

Domenico Lapenna1, Sante D Pierdomenico, Giuliano Ciofani, Sante Ucchino, Matteo Neri, Maria Adele Giamberardino, Franco Cuccurullo.   

Abstract

The association between iron, an oxidant catalyst, and atherosclerosis is controversial. In particular, it is unknown whether: (1) stored iron, namely serum ferritin, is correlated with catalytic iron and oxidant damage of human atherosclerotic plaques; (2) catalytic iron is related to oxidative injury within such plaques; (3) plaque oxidant burden is associated with the severity of atherosclerosis. Thus, we assessed low molecular weight iron (LMWI), which represents the metal catalytically active form, together with fluorescent damage products of lipid peroxidation (FDPL) and lipid hydroperoxides (LOOH), in 38 atherosclerotic plaques surgically removed from 38 patients who had undergone selective carotid endarterectomy. In each patient, the levels of serum ferritin were measured and correlated with those of plaque LMWI and lipoperoxides by the Spearman rank correlation test with Spearman rank correlation coefficient (r(S)) calculation. Moreover, in patients selected from the same study population, we compared plaque analyte levels between two groups with different severity of atherosclerotic carotid stenosis, i.e., <90% (group A, n = 25) or > or =90% (group B, n = 13), and between another two groups without (group C, n = 27) and with (group D, n = 11) associated contralateral carotid stenosis > or =50%, indicative of "extensive" and more severe atherosclerotic disease. In group A patients, serum ferritin was directly and significantly correlated with plaque LMWI (r(S) = 0.46, P < 0.025) and FDPL (r(S) = 0.58, P < 0.005), while its correlation with plaque LOOH, albeit direct, did not attain statistical significance. Moreover, a direct and significant relationship was evident between the plaque content of LMWI and that of both FDPL (r(S) = 0.61, P < 0.0025) and LOOH (r(S) = 0.51, P < 0.025), suggesting a prooxidant role of catalytic iron within human atherosclerotic plaques. Considering the 13 patients of group B, a positive and significant correlation was observed between the levels of serum ferritin and those of plaque LMWI (r(S) = 0.83, P < 0.0001); on the other hand, serum ferritin, as well as plaque LMWI, showed no significant correlation with either plaque FDPL or LOOH, conceivably reflecting the small number of patients belonging to group B. Finally, plaque LMWI, FDPL, and LOOH content was significantly higher in group B than in group A, and in group D than in group C. These data suggest a role for catalytic iron in atherosclerotic plaque oxidation and in the severity of atherosclerosis, which appears indeed associated with plaque oxidant burden.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17275681     DOI: 10.1016/j.freeradbiomed.2006.11.014

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  12 in total

Review 1.  The big idea: the coxib crisis iron, aspirin and heart disease risk revisited.

Authors:  Jerome L Sullivan
Journal:  J R Soc Med       Date:  2007-07       Impact factor: 5.344

2.  Liver X receptor activation stimulates iron export in human alternative macrophages.

Authors:  Gaël Bories; Sophie Colin; Jonathan Vanhoutte; Bruno Derudas; Corinne Copin; Mélanie Fanchon; Mehdi Daoudi; Loïc Belloy; Stephan Haulon; Christophe Zawadzki; Brigitte Jude; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Circ Res       Date:  2013-09-13       Impact factor: 17.367

3.  Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration.

Authors:  Vaijinath S Kamanna; Shobha H Ganji; Stanislav Shelkovnikov; Keith Norris; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2011-12-29       Impact factor: 3.754

4.  Association of serum bilirubin with oxidant damage of human atherosclerotic plaques and the severity of atherosclerosis.

Authors:  Domenico Lapenna; Giuliano Ciofani; Sante Donato Pierdomenico; Maria Adele Giamberardino; Sante Ucchino; Giovanni Davì
Journal:  Clin Exp Med       Date:  2017-09-25       Impact factor: 3.984

Review 5.  The role of hepcidin and iron homeostasis in atherosclerosis.

Authors:  Florian Wunderer; Lisa Traeger; Haakon H Sigurslid; Patrick Meybohm; Donald B Bloch; Rajeev Malhotra
Journal:  Pharmacol Res       Date:  2020-01-25       Impact factor: 7.658

6.  Microcalcifications in atherosclerotic lesion of apolipoprotein E-deficient mouse.

Authors:  Nicola Debernardi; Ruben B Roijers; Rob Krams; Rini de Crom; Peter H A Mutsaers; Ger J van der Vusse
Journal:  Int J Exp Pathol       Date:  2010-08-27       Impact factor: 1.925

Review 7.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

Review 8.  Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin.

Authors:  Giuseppina Pisano; Rosa Lombardi; Anna Ludovica Fracanzani
Journal:  Int J Mol Sci       Date:  2016-05-05       Impact factor: 5.923

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

10.  Iron and hepcidin as risk factors in atherosclerosis: what do the genes say?

Authors:  Tessel E Galesloot; Luc L Janss; Stephen Burgess; Lambertus A L M Kiemeney; Martin den Heijer; Jacqueline de Graaf; Suzanne Holewijn; Beben Benyamin; John B Whitfield; Dorine W Swinkels; Sita H Vermeulen
Journal:  BMC Genet       Date:  2015-07-11       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.